Just to complete the PXS comparson - PXS has sunk over $300m in equity so far and prior to the $40m payment had a cash burn year of $20m+ so PYC having any sliver of success on the Genetech deal should result in a reasonable share price performance. Shareholders in PXS are mindful of the cash burn and the need for continued progress payments for their survival - an equity raising to cover their cash burn could be crippling. PYC on the other hand could find that by the end of next year they are self sufficient as they are much smaller scale on the burn front - not quite as sharp as ADO but still relatively manageable.
I don't think it is reasonable to complain on one hand that the company slinks away with no reporting if something goes wrong and then when they attempt to provide shareholders with more transparent information regarding timetables and expectations then it is comical.
PYC Price at posting:
1.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)